Correlation of miR-29c and miR-223 expression with other markers and prognostic value
| . | n . | Percent . | miR-29c expression* . | P . | miR-223 expression* . | P . | Median TFS (mo) . | P . | χ2(1) . | Median OS (mo) . | P . | χ2(1) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | 110 | |||||||||||
| Male | 68 | 62 | 10.93 ± 1.93 | .832 | 173.6 ± 20.98 | .497 | 60.9 | .760 | 0.09 | 241.9 | .922 | 0.01 |
| Female | 42 | 38 | 8.02 ± 1.59 | 133.7 ± 13.99 | 57.3 | 237.1 | ||||||
| Binet | 110 | |||||||||||
| Stage A | 77 | 70 | 11.82 ± 1.79 | .001 | 175.6 ± 18.91 | .018 | 87 | < .001 | 11.61 | 137.2 | .009 | 6.76 |
| Stage B | 22 | 20 | 4.81 ± 0.97 | 117.0 ± 14.38 | ||||||||
| Stage C | 11 | 10 | 2.37 ± 0.60 | 70.97 ± 15.2 | 24 | Not reached | ||||||
| miR-29c* | 110 | |||||||||||
| < 4.64 (negative) | 49 | 45 | 95.11 ± 9.83 | < .001 | 24.2 | .002 | 10.09 | 183 | .023 | 5.14 | ||
| > 4.64 (positive) | 61 | 55 | 209.2 ± 22.19 | 101 | Not reached | |||||||
| miR-223* | 110 | |||||||||||
| < 82.69 (negative) | 37 | 34 | 4.67 ± 1.13 | < .001 | 24.1 | < .001 | 15.79 | 137.2 | .001 | 11.25 | ||
| > 82.69 (positive) | 73 | 66 | 12.43 ± 1.87 | 107.2 | Not reached | |||||||
| Mutational status† | 104 | |||||||||||
| IgVH-unmutated | 46 | 44 | 4.97 ± 0.88 | .001 | 108.5 ± 15.52 | < .001 | 24 | < .001 | 27.99 | 106.2 | < .001 | 15.01 |
| IgVH-mutated | 58 | 56 | 12.61 ± 2.16 | 190.5 ± 19.26 | 129.5 | Not reached | ||||||
| ZAP70‡ | 110 | |||||||||||
| > 134 (positive) | 53 | 48 | 5.76 ± 0.96 | .003 | 107.6 ± 11.95 | < .001 | 24 | < .001 | 36.33 | 137.2 | < .001 | 16.09 |
| < 134 (negative) | 57 | 57 | 12.95 ± 2.29 | 205.6 ± 23.25 | 157 | Not reached | ||||||
| LPL‡ | 110 | |||||||||||
| > 6 (positive) | 49 | 45 | 4.85 ± 0.79 | .001 | 96.49 ± 10.92 | < .001 | 24.1 | < .001 | 12.57 | 152.5 | .028 | 4.82 |
| < 6 (negative) | 61 | 55 | 13.38 ± 2.21 | 208.1 ± 21.95 | 126 | 241.9 | ||||||
| CD38‡ | 104 | |||||||||||
| > 7% (positive) | 47 | 45 | 5.79 ± 0.88 | .017 | 115.5 ± 10.72 | .013 | 29 | .003 | 8.59 | 152.5 | .014 | 6.00 |
| < 7% (negative) | 57 | 55 | 13.14 ± 2.33 | 198.4 ± 24.23 | 126 | 241.9 | ||||||
| LDT | 93 | |||||||||||
| < 1 y | 21 | 23 | 2.77 ± 0.56 | < .001 | 94.43 ± 14.72 | .01 | 11 | < .001 | 36.39 | 82.8 | < .001 | 11.74 |
| > 1 y | 72 | 77 | 11.66 ± 1.82 | 172.7 ± 16.90 | 107.2 | 237.1 | ||||||
| β2-microglubulin‡ | 78 | |||||||||||
| > 2.77 μg (positive) | 28 | 36 | 5.63 ± 1.31 | .007 | 94.13 ± 13.73 | .001 | 35.5 | .046 | 3.97 | 152.5 | .003 | 8.89 |
| < 2.77 μg (negative) | 50 | 64 | 13.48 ± 2.47 | 191.3 ± 22.73 | 93.8 | Not reached | ||||||
| Soluble CD23‡ | 91 | |||||||||||
| > 120 U (positive) | 47 | 57 | 3.32 ± 0.41 | < .001 | 103.3 ± 9.795 | < .001 | 28.6 | .015 | 5.92 | 183 | .016 | 5.82 |
| < 120 U (negative) | 44 | 53 | 15.69 ± 2.87 | 217.5 ± 26.10 | 101 | Not reached | ||||||
| Cytogenetic abnormalities§ | 81 | |||||||||||
| del(17p), (11q), (6q), +12, complex | 35 | 43 | 6.346 ± 1.38 | .023 | 100.7 ± 11.47 | < .001 | 35.5 | .001 | 10.44 | 137.2 | .004 | 8.24 |
| Normal, del(13q), other | 46 | 57 | 12.33 ± 2.21 | 207.2 ± 24.67 | 157 | Not reached | ||||||
| Patients not requiring treatment | 49 | 45 | 14.21 ± 2.23 | < .001 | 213.2 ± 26.50 | < .001 | ||||||
| Patients requiring treatment | 61 | 55 | 4.97 ± 0.71 | 114.4 ± 11.29 | ||||||||
| Patients still alive | 90 | 82 | 11.27 ± 1.59 | < .001 | 177.3 ± 16.35 | < .001 | ||||||
| Patients died during the study | 20 | 18 | 3.32 ± 0.95 | 73.08 ± 12.88 |
| . | n . | Percent . | miR-29c expression* . | P . | miR-223 expression* . | P . | Median TFS (mo) . | P . | χ2(1) . | Median OS (mo) . | P . | χ2(1) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | 110 | |||||||||||
| Male | 68 | 62 | 10.93 ± 1.93 | .832 | 173.6 ± 20.98 | .497 | 60.9 | .760 | 0.09 | 241.9 | .922 | 0.01 |
| Female | 42 | 38 | 8.02 ± 1.59 | 133.7 ± 13.99 | 57.3 | 237.1 | ||||||
| Binet | 110 | |||||||||||
| Stage A | 77 | 70 | 11.82 ± 1.79 | .001 | 175.6 ± 18.91 | .018 | 87 | < .001 | 11.61 | 137.2 | .009 | 6.76 |
| Stage B | 22 | 20 | 4.81 ± 0.97 | 117.0 ± 14.38 | ||||||||
| Stage C | 11 | 10 | 2.37 ± 0.60 | 70.97 ± 15.2 | 24 | Not reached | ||||||
| miR-29c* | 110 | |||||||||||
| < 4.64 (negative) | 49 | 45 | 95.11 ± 9.83 | < .001 | 24.2 | .002 | 10.09 | 183 | .023 | 5.14 | ||
| > 4.64 (positive) | 61 | 55 | 209.2 ± 22.19 | 101 | Not reached | |||||||
| miR-223* | 110 | |||||||||||
| < 82.69 (negative) | 37 | 34 | 4.67 ± 1.13 | < .001 | 24.1 | < .001 | 15.79 | 137.2 | .001 | 11.25 | ||
| > 82.69 (positive) | 73 | 66 | 12.43 ± 1.87 | 107.2 | Not reached | |||||||
| Mutational status† | 104 | |||||||||||
| IgVH-unmutated | 46 | 44 | 4.97 ± 0.88 | .001 | 108.5 ± 15.52 | < .001 | 24 | < .001 | 27.99 | 106.2 | < .001 | 15.01 |
| IgVH-mutated | 58 | 56 | 12.61 ± 2.16 | 190.5 ± 19.26 | 129.5 | Not reached | ||||||
| ZAP70‡ | 110 | |||||||||||
| > 134 (positive) | 53 | 48 | 5.76 ± 0.96 | .003 | 107.6 ± 11.95 | < .001 | 24 | < .001 | 36.33 | 137.2 | < .001 | 16.09 |
| < 134 (negative) | 57 | 57 | 12.95 ± 2.29 | 205.6 ± 23.25 | 157 | Not reached | ||||||
| LPL‡ | 110 | |||||||||||
| > 6 (positive) | 49 | 45 | 4.85 ± 0.79 | .001 | 96.49 ± 10.92 | < .001 | 24.1 | < .001 | 12.57 | 152.5 | .028 | 4.82 |
| < 6 (negative) | 61 | 55 | 13.38 ± 2.21 | 208.1 ± 21.95 | 126 | 241.9 | ||||||
| CD38‡ | 104 | |||||||||||
| > 7% (positive) | 47 | 45 | 5.79 ± 0.88 | .017 | 115.5 ± 10.72 | .013 | 29 | .003 | 8.59 | 152.5 | .014 | 6.00 |
| < 7% (negative) | 57 | 55 | 13.14 ± 2.33 | 198.4 ± 24.23 | 126 | 241.9 | ||||||
| LDT | 93 | |||||||||||
| < 1 y | 21 | 23 | 2.77 ± 0.56 | < .001 | 94.43 ± 14.72 | .01 | 11 | < .001 | 36.39 | 82.8 | < .001 | 11.74 |
| > 1 y | 72 | 77 | 11.66 ± 1.82 | 172.7 ± 16.90 | 107.2 | 237.1 | ||||||
| β2-microglubulin‡ | 78 | |||||||||||
| > 2.77 μg (positive) | 28 | 36 | 5.63 ± 1.31 | .007 | 94.13 ± 13.73 | .001 | 35.5 | .046 | 3.97 | 152.5 | .003 | 8.89 |
| < 2.77 μg (negative) | 50 | 64 | 13.48 ± 2.47 | 191.3 ± 22.73 | 93.8 | Not reached | ||||||
| Soluble CD23‡ | 91 | |||||||||||
| > 120 U (positive) | 47 | 57 | 3.32 ± 0.41 | < .001 | 103.3 ± 9.795 | < .001 | 28.6 | .015 | 5.92 | 183 | .016 | 5.82 |
| < 120 U (negative) | 44 | 53 | 15.69 ± 2.87 | 217.5 ± 26.10 | 101 | Not reached | ||||||
| Cytogenetic abnormalities§ | 81 | |||||||||||
| del(17p), (11q), (6q), +12, complex | 35 | 43 | 6.346 ± 1.38 | .023 | 100.7 ± 11.47 | < .001 | 35.5 | .001 | 10.44 | 137.2 | .004 | 8.24 |
| Normal, del(13q), other | 46 | 57 | 12.33 ± 2.21 | 207.2 ± 24.67 | 157 | Not reached | ||||||
| Patients not requiring treatment | 49 | 45 | 14.21 ± 2.23 | < .001 | 213.2 ± 26.50 | < .001 | ||||||
| Patients requiring treatment | 61 | 55 | 4.97 ± 0.71 | 114.4 ± 11.29 | ||||||||
| Patients still alive | 90 | 82 | 11.27 ± 1.59 | < .001 | 177.3 ± 16.35 | < .001 | ||||||
| Patients died during the study | 20 | 18 | 3.32 ± 0.95 | 73.08 ± 12.88 |
miR values are expressed in fold of target miR expression in the calibrator cell line (Namalwa).
Mutational status is based on a 98% cutoff value.
The cutoff determined using ROC curve analysis maximizing the concordance with the IgVH status.
Among patients with unfavorable cytogenetic abnormalities (n = 35), we found 7 patients with a del(17p) (8.6%), 7 with a del(11q) (8.6%), 8 with del(6q) (9.9%), and 12 with a trisomy-12 (14.8%). Furthermore, 1 patient presents a complex karyotype associated with poor prognosis (1.2%). Among patients with favorable cytogenetic abnormalities (n = 24), we found 22 patients with del(13q) (27.2%) and 2 patients with other abnormalities [del(16q) and translocation t(13,14)] (2.4%). Twenty-two patients had a normal karyotype (25.9%).